Publication

Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis

Arshad, F., Stoof, S. C. M., Leebeek, F. W. G., Ruitenbeek, K., Adelmeijer, J., Blokzijl, H., van den Berg, A. P., Porte, R. J., Kruip, M. J. H. A. & Lisman, T., Jul-2015, In : Liver International. 35, 7, p. 1809-1815 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis

    Final publisher's version, 1.39 MB, PDF document

    Request copy

DOI

Background & AimsCirrhosis frequently affects multiple components of hemostasis. Reversal of the coagulopathy of these patients is frequently required in case of bleeding episodes, or as prophylaxis before invasive procedures. Although 1-deamino-8-D-arginine vasopressin (DDAVP) is widely used as a pro-hemostatic agent in patients with cirrhosis, it is unclear whether DDAVP truly enhances hemostasis in these patients. Here we investigated the hemostatic effects of a single bolus of DDAVP in patients with cirrhosis.

MethodsTen patients with cirrhosis (child B or C) and ten patients with mild haemophilia A received an intravenous single bolus of 0.3 microgram/kg DDAVP. Plasma was collected prior to and at 1, 3, 6, and 24h after DDAVP administration. Levels of Von Willebrand factor (VWF), VWF propeptide, factor VIII (FVIII), and ADAMTS13 were measured in all plasma samples, whereas VWF multimers and functional VWF-dependent platelet adhesion were determined in the samples pre- and 1h after DDAVP administration.

ResultsFollowing DDAVP administration, VWF, FVIII, and VWF propeptide levels increased in patients with haemophilia, while patients with cirrhosis only showed an increase in VWF propeptide and FVIII levels. High molecular weight VWF multimers and VWF-dependent platelet adhesion increased in patients with haemophilia one hour after DDAVP administration, but did not change in the patients with cirrhosis. Levels of ADAMTS13 were unaffected in both patient groups after DDAVP.

ConclusionThe lack of relevant effects of DDAVP on laboratory indices of primary hemostasis in patients with cirrhosis is in line with previous clinical study results in these patients.

Original languageEnglish
Pages (from-to)1809-1815
Number of pages7
JournalLiver International
Volume35
Issue number7
Publication statusPublished - Jul-2015

    Keywords

  • cirrhosis, desmopressin, haemophilia, platelet, von Willebrand factor, VON-WILLEBRAND-FACTOR, PROLONGED BLEEDING-TIME, LIVER-DISEASE, ADAMTS13 ACTIVITY, DESMOPRESSIN DDAVP, PLATELET-FUNCTION, CONTROLLED-TRIAL, STELLATE CELLS, THROMBOSIS

ID: 21925422